HC Wainwright Reaffirms “Buy” Rating for Connect Biopharma (NASDAQ:CNTB)

Posted by Brenda Bartman on Oct 8th, 2026

Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Thursday, Marketbeat reports. HC Wainwright also issued estimates for Connect Biopharma’s Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.67) EPS, FY2028 earnings at ($0.94) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($1.16) EPS.

Other research analysts also recently issued research reports about the stock. BTIG Research dropped their price objective on shares of Connect Biopharma to $5.00 and set a “buy” rating for the company in a report on Wednesday, September 30th. Piper Sandler assumed coverage on shares of Connect Biopharma in a report on Friday, June 26th. They set an “overweight” rating and a $7.00 price objective for the company. Oppenheimer dropped their price objective on shares of Connect Biopharma to $5.00 and set an “outperform” rating for the company in a report on Tuesday, September 22nd. Weiss Ratings raised shares of Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. Finally, Wall Street Zen raised shares of Connect Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.14.

Get Our Latest Stock Report on CNTB

Connect Biopharma Price Performance

CNTB stock traded down $0.04 during trading on Thursday, reaching $0.91. The company’s stock had a trading volume of 762,440 shares, compared to its average volume of 1,439,480. Connect Biopharma has a 1 year low of $0.85 and a 1 year high of $3.82. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $57.18 million, a P/E ratio of -0.76 and a beta of -0.16. The company’s fifty day moving average is $1.83 and its 200-day moving average is $2.23.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.04. The company had revenue of $2.75 million for the quarter, compared to the consensus estimate of $0.74 million. On average, research analysts expect that Connect Biopharma will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Connect Biopharma

Institutional investors have recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC bought a new stake in Connect Biopharma in the first quarter worth about $1,945,000. Bank of America Corp DE bought a new stake in Connect Biopharma in the first quarter worth about $41,000. Knott David M Jr lifted its stake in Connect Biopharma by 93.9% in the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after purchasing an additional 187,835 shares during the last quarter. Simplify Asset Management Inc. bought a new stake in Connect Biopharma in the first quarter worth about $135,000. Finally, Richmond Brothers Inc. bought a new stake in Connect Biopharma in the fourth quarter worth about $489,000. Institutional investors own 58.72% of the company’s stock.

About Connect Biopharma

(Get Free Report)

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.